These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 15372159)

  • 21. Neuropsychological and olfactory dysfunction in schizophrenia: relationship of frontal syndromes to syndromes of schizophrenia.
    Pantelis C; Brewer W
    Schizophr Res; 1995 Sep; 17(1):35-45. PubMed ID: 8541248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specificity of prefrontal dysfunction and context processing deficits to schizophrenia in never-medicated patients with first-episode psychosis.
    MacDonald AW; Carter CS; Kerns JG; Ursu S; Barch DM; Holmes AJ; Stenger VA; Cohen JD
    Am J Psychiatry; 2005 Mar; 162(3):475-84. PubMed ID: 15741464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Altered reward functions in patients on atypical antipsychotic medication in line with the revised dopamine hypothesis of schizophrenia.
    Walter H; Kammerer H; Frasch K; Spitzer M; Abler B
    Psychopharmacology (Berl); 2009 Sep; 206(1):121-32. PubMed ID: 19521678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Deficit schizophrenia: from pharmacology to clinical practice].
    Tassin JP
    Encephale; 1996 Jun; 22 Spec No 2():9-12. PubMed ID: 8767035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Negative symptoms in schizophrenia: neurobiological models and treatment response.
    Goff DC; Evins AE
    Harv Rev Psychiatry; 1998; 6(2):59-77. PubMed ID: 10370450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Restoring GABAergic signaling and neuronal synchrony in schizophrenia.
    Akbarian S
    Am J Psychiatry; 2008 Dec; 165(12):1507-9. PubMed ID: 19047328
    [No Abstract]   [Full Text] [Related]  

  • 27. A functional promoter polymorphism of neuronal nitric oxide synthase moderates prefrontal functioning in schizophrenia.
    Reif A; Schecklmann M; Eirich E; Jacob CP; Jarczok TA; Kittel-Schneider S; Lesch KP; Fallgatter AJ; Ehlis AC
    Int J Neuropsychopharmacol; 2011 Aug; 14(7):887-97. PubMed ID: 21281558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct effects of duration of untreated psychosis on brain cortical activities in different treatment phases of schizophrenia: a multi-channel near-infrared spectroscopy study.
    Chou PH; Koike S; Nishimura Y; Kawasaki S; Satomura Y; Kinoshita A; Takizawa R; Kasai K
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Mar; 49():63-9. PubMed ID: 24275075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Schizophrenia: a computational reinforcement learning perspective.
    Frank MJ
    Schizophr Bull; 2008 Nov; 34(6):1008-11. PubMed ID: 18791075
    [No Abstract]   [Full Text] [Related]  

  • 30. Functional and anatomical aspects of prefrontal pathology in schizophrenia.
    Goldman-Rakic PS; Selemon LD
    Schizophr Bull; 1997; 23(3):437-58. PubMed ID: 9327508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Value of brain imaging in assessment of cognitive symptoms. Cognitive and emotional impact of antipsychotic drug treatment]].
    Martinot JL; Peretti CS
    Encephale; 2006 Jan; 32 Pt 2():S3-5. PubMed ID: 16800076
    [No Abstract]   [Full Text] [Related]  

  • 32. Hyperresponsivity and impaired prefrontal control of the mesolimbic reward system in schizophrenia.
    Richter A; Petrovic A; Diekhof EK; Trost S; Wolter S; Gruber O
    J Psychiatr Res; 2015 Dec; 71():8-15. PubMed ID: 26522867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On localizing schizophrenic neuropathology.
    Weinberger DR
    Schizophr Bull; 1997; 23(3):537-40. PubMed ID: 9327520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prefrontal lobe dysfunction predicts treatment response in medication-naive first-episode schizophrenia.
    van Veelen NM; Vink M; Ramsey NF; van Buuren M; Hoogendam JM; Kahn RS
    Schizophr Res; 2011 Jul; 129(2-3):156-62. PubMed ID: 21497488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cognitive neuroscience of memory function and dysfunction in schizophrenia.
    Ranganath C; Minzenberg MJ; Ragland JD
    Biol Psychiatry; 2008 Jul; 64(1):18-25. PubMed ID: 18495087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of cerebral deficits with clinical symptoms in antipsychotic-naive first-episode schizophrenia: an optimized voxel-based morphometry and resting state functional connectivity study.
    Lui S; Deng W; Huang X; Jiang L; Ma X; Chen H; Zhang T; Li X; Li D; Zou L; Tang H; Zhou XJ; Mechelli A; Collier DA; Sweeney JA; Li T; Gong Q
    Am J Psychiatry; 2009 Feb; 166(2):196-205. PubMed ID: 18981063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hypofrontality and negative symptoms in schizophrenia: synthesis of anatomic and neuropsychological knowledge and ecological perspectives].
    Semkovska M; Bédard MA; Stip E
    Encephale; 2001; 27(5):405-15. PubMed ID: 11760690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional magnetic resonance imaging investigation of the amphetamine sensitization model of schizophrenia in healthy male volunteers.
    O'Daly OG; Joyce D; Stephan KE; Murray RM; Shergill SS
    Arch Gen Psychiatry; 2011 Jun; 68(6):545-54. PubMed ID: 21300940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolcapone, COMT polymorphisms and pharmacogenomic treatment of schizophrenia.
    Bitsios P; Roussos P
    Pharmacogenomics; 2011 Apr; 12(4):559-66. PubMed ID: 21521027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abnormal neural integration related to cognition in schizophrenia.
    Dolan RJ; Fletcher PC; McKenna P; Friston KJ; Frith CD
    Acta Psychiatr Scand Suppl; 1999; 395():58-67. PubMed ID: 10225334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.